IL144793A0 - Process for the production of tert-butyl (e)-(6-[2[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl] (4r,6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate - Google Patents
Process for the production of tert-butyl (e)-(6-[2[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl] (4r,6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetateInfo
- Publication number
- IL144793A0 IL144793A0 IL14479300A IL14479300A IL144793A0 IL 144793 A0 IL144793 A0 IL 144793A0 IL 14479300 A IL14479300 A IL 14479300A IL 14479300 A IL14479300 A IL 14479300A IL 144793 A0 IL144793 A0 IL 144793A0
- Authority
- IL
- Israel
- Prior art keywords
- dioxan
- methylsulfonyl
- pyrimidin
- fluorophenyl
- tert
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9903472.0A GB9903472D0 (en) | 1999-02-17 | 1999-02-17 | Chemical process |
PCT/GB2000/000481 WO2000049014A1 (en) | 1999-02-17 | 2000-02-15 | Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate |
Publications (1)
Publication Number | Publication Date |
---|---|
IL144793A0 true IL144793A0 (en) | 2002-06-30 |
Family
ID=10847843
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14479300A IL144793A0 (en) | 1999-02-17 | 2000-02-15 | Process for the production of tert-butyl (e)-(6-[2[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl] (4r,6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate |
IL163375A IL163375A (en) | 1999-02-17 | 2004-08-05 | Protected dihydroxy acid derivatives and processes for the preparation of an intermediate substance oxide diphenylposphine for them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL163375A IL163375A (en) | 1999-02-17 | 2004-08-05 | Protected dihydroxy acid derivatives and processes for the preparation of an intermediate substance oxide diphenylposphine for them |
Country Status (34)
Country | Link |
---|---|
US (2) | US6844437B1 (xx) |
EP (1) | EP1155015B1 (xx) |
JP (3) | JP2003518474A (xx) |
KR (1) | KR100648160B1 (xx) |
CN (1) | CN1145625C (xx) |
AR (1) | AR022600A1 (xx) |
AT (1) | ATE415398T1 (xx) |
AU (1) | AU760145B2 (xx) |
BR (1) | BRPI0008301B8 (xx) |
CA (1) | CA2362594C (xx) |
CL (1) | CL2003002336A1 (xx) |
CY (1) | CY1108733T1 (xx) |
CZ (1) | CZ299844B6 (xx) |
DE (1) | DE60040905D1 (xx) |
DK (1) | DK1155015T3 (xx) |
EE (2) | EE05150B1 (xx) |
ES (1) | ES2316349T3 (xx) |
GB (1) | GB9903472D0 (xx) |
HK (1) | HK1041265B (xx) |
HU (1) | HU229835B1 (xx) |
IL (2) | IL144793A0 (xx) |
IS (1) | IS2709B3 (xx) |
MX (1) | MXPA01008235A (xx) |
NO (1) | NO320739B1 (xx) |
NZ (1) | NZ513261A (xx) |
PL (1) | PL218518B1 (xx) |
PT (1) | PT1155015E (xx) |
RU (1) | RU2243969C2 (xx) |
SI (1) | SI1155015T1 (xx) |
SK (1) | SK286988B6 (xx) |
TR (2) | TR200102360T2 (xx) |
TW (1) | TWI285202B (xx) |
WO (1) | WO2000049014A1 (xx) |
ZA (1) | ZA200106370B (xx) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9902202D0 (sv) * | 1999-06-10 | 1999-06-10 | Astra Ab | Production of aggregates |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
GB0011120D0 (en) | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
NL1015744C2 (nl) * | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
DK1417180T3 (da) | 2001-07-13 | 2007-04-10 | Astrazeneca Uk Ltd | Fremstilling af aminopyrimidinforbindelser |
CA2450820C (en) * | 2001-08-16 | 2011-03-15 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
EP1323717A1 (en) * | 2001-12-27 | 2003-07-02 | Dsm N.V. | Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives |
EP1375493A1 (en) * | 2002-06-17 | 2004-01-02 | Dsm N.V. | Process for the preparation of an dioxane acetic acid ester |
GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
KR101060215B1 (ko) * | 2002-12-16 | 2011-08-29 | 아스트라제네카 유케이 리미티드 | 피리미딘 화합물의 제조 방법 |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
EP1562912A2 (en) | 2003-08-28 | 2005-08-17 | Teva Pharmaceutical Industries Limited | Process for preparation of rosuvastatin calcium |
UY28501A1 (es) * | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0321827D0 (en) * | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
CA2546701C (en) | 2003-11-24 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
KR100887264B1 (ko) | 2003-12-02 | 2009-03-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 로수바스타틴의 특성화를 위한 기준 표준물 |
US7241800B2 (en) | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
GB0406757D0 (en) | 2004-03-26 | 2004-04-28 | Avecia Ltd | Process and compounds |
US7179916B2 (en) | 2004-07-13 | 2007-02-20 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin |
GB0427491D0 (en) | 2004-12-16 | 2005-01-19 | Avecia Ltd | Process and compounds |
GB0428328D0 (en) | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
CN100351240C (zh) * | 2005-01-19 | 2007-11-28 | 安徽省庆云医药化工有限公司 | 瑞舒伐他汀钙的合成方法 |
ES2389565T3 (es) | 2005-02-22 | 2012-10-29 | Teva Pharmaceutical Industries Ltd. | Rosuvastatina y sales de la misma carentes de alquiléter de rosuvatatina y un procedimiento para la preparación de las mismas |
US20090124803A1 (en) * | 2005-03-22 | 2009-05-14 | Pandurang Balwant Deshpande | Process for preparation of rosuvastatin |
WO2006106526A1 (en) * | 2005-04-04 | 2006-10-12 | Unichem Laboratories Limited | Process for preparation of calcium salt of rosuvastatin |
HU227120B1 (hu) * | 2005-05-26 | 2010-07-28 | Richter Gedeon Nyrt | Eljárás rosuvastatin kalciumsójának elõállítására új intermediereken keresztül |
US9150518B2 (en) * | 2005-06-24 | 2015-10-06 | Lek Pharmaceuticals, D.D. | Process for preparing amorphous rosuvastatin calcium of impurities |
ES2564807T5 (es) | 2005-06-24 | 2019-02-26 | Lek Pharmaceuticals | Proceso para preparación de rosuvastatina de calcio amorfa pura |
GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
US8354530B2 (en) | 2005-07-28 | 2013-01-15 | Lek Pharmaceuticals d. d | Process for the synthesis of rosuvastatin calcium |
WO2007022488A2 (en) | 2005-08-16 | 2007-02-22 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
CN100436428C (zh) * | 2005-08-22 | 2008-11-26 | 鲁南制药集团股份有限公司 | 瑞舒伐他汀及其盐的制备方法 |
CN100352821C (zh) * | 2005-08-22 | 2007-12-05 | 鲁南制药集团股份有限公司 | 一种瑞舒伐他汀钙中间体的制备方法 |
US8455640B2 (en) * | 2006-05-03 | 2013-06-04 | Msn Laboratories Limited | Process for statins and its pharmaceutically acceptable salts thereof |
US8404841B2 (en) * | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
WO2008053334A2 (en) | 2006-10-31 | 2008-05-08 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin calcium |
TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
WO2008072078A1 (en) | 2006-12-13 | 2008-06-19 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin caclium |
ES2385623T3 (es) | 2007-02-08 | 2012-07-27 | Aurobindo Pharma Limited | Un procedimiento mejorado para la preparación de rosuvastatina cálcica |
EP2032586A2 (en) | 2007-04-18 | 2009-03-11 | Teva Pharmaceutical Industries Ltd. | A process for preparing intermediates of hmg-coa reductase inhibitors |
EP2178846A1 (en) | 2007-07-12 | 2010-04-28 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin intermediates and their preparation |
EP2223909A1 (en) | 2007-08-28 | 2010-09-01 | Ratiopharm GmbH | Process for preparing pentanoic diacid derivatives |
CN101376647B (zh) * | 2007-08-31 | 2010-12-08 | 中山奕安泰医药科技有限公司 | 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法 |
US8653265B2 (en) | 2008-05-27 | 2014-02-18 | Changzhou Pharmaceutical Factory | Preparation method of rosuvastatin calcium and its intermediates |
PL2309992T3 (pl) | 2008-06-27 | 2018-05-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kompozycja farmaceutyczna zawierająca statynę |
EP2138165A1 (en) | 2008-06-27 | 2009-12-30 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising a statin |
US20110245285A1 (en) * | 2008-09-09 | 2011-10-06 | Biocon Limited | Process for preparation of rosuvastatin acetonide calcium |
WO2010038124A1 (en) * | 2008-09-30 | 2010-04-08 | Aurobindo Pharma Limited | An improved process for preparing pyrimidine propenaldehyde |
EP2351762B1 (en) | 2008-10-20 | 2013-10-16 | Kaneka Corporation | NOVEL PYRIMIDINE DERIVATIVE AND METHOD FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR INTERMEDIATE |
EP2327682A1 (en) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
SI2373609T1 (sl) | 2008-12-19 | 2013-12-31 | Krka, D.D., Novo Mesto | Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov |
KR20100080432A (ko) * | 2008-12-29 | 2010-07-08 | 한미약품 주식회사 | 스타틴 화합물의 신규 제조방법 및 이에 사용되는 벤조티아졸릴 술폰 화합물 |
EP2752407B1 (en) | 2009-01-14 | 2015-09-23 | Krka Tovarna Zdravil, D.D., Novo Mesto | Crystalline rosuvastatin calcium trihydrate |
EP2387561A4 (en) | 2009-01-19 | 2012-07-25 | Msn Lab Ltd | IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
KR101157314B1 (ko) * | 2009-06-05 | 2012-06-15 | 주식회사종근당 | 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법 |
US8987444B2 (en) | 2010-01-18 | 2015-03-24 | Msn Laboratories Private Limited | Process for the preparation of amide intermediates and their use thereof |
WO2011104725A2 (en) | 2010-02-23 | 2011-09-01 | Cadila Healthcare Limited | Hmg-coa reductase inhibitors and process for the preparation thereof |
WO2012011129A2 (en) * | 2010-07-22 | 2012-01-26 | Msn Laboratories Limited | Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt |
WO2012073256A1 (en) | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
MX2013008285A (es) | 2011-01-18 | 2013-09-13 | Dsm Sinochem Pharm Bv | Procedimiento para la preparacion de diolsulfonas. |
CN103313983B (zh) * | 2011-01-18 | 2016-06-29 | 中化帝斯曼制药有限公司荷兰公司 | 在碱存在下制备他汀类化合物的方法 |
US8865900B2 (en) | 2011-01-18 | 2014-10-21 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Methyltetrazole sulfides and sulfones |
WO2012172564A1 (en) * | 2011-05-25 | 2012-12-20 | Dr. Reddy's Laboratories Limited | Process for preparation of rosuvastatin calcium |
MX363563B (es) | 2011-12-09 | 2019-03-27 | Dsm Sinochem Pharm Nl Bv | Proceso para la preparación de un tioprecursor de estatinas. |
MX359424B (es) | 2011-12-09 | 2018-09-12 | Dsm Sinochem Pharm Nl Bv | Proceso para la preparación de un precursor de estatina. |
KR20130087153A (ko) * | 2012-01-27 | 2013-08-06 | 코오롱생명과학 주식회사 | 로수바스타틴의 제조방법 및 이에 사용되는 중간체 화합물 |
CN103232398B (zh) * | 2012-04-28 | 2016-04-06 | 上海科州药物研发有限公司 | 一种瑞舒伐他汀氨基酸盐及其制备方法和应用 |
KR101292743B1 (ko) * | 2012-05-17 | 2013-08-02 | (주) 에프엔지리서치 | 신규한 스타틴 중간체 및 이를 이용한 피타바스타틴, 로수바스타틴, 세리바스타틴 및 플루바스타틴의 제조 방법 |
CN103864697A (zh) * | 2012-12-11 | 2014-06-18 | 润泽制药(苏州)有限公司 | 瑞舒伐中间体主链醇的制备方法 |
WO2014108795A2 (en) | 2013-01-10 | 2014-07-17 | Aurobindo Pharma Limited | An improved process for the preparation of chiral diol sulfones and statins |
CN103420919B (zh) * | 2013-08-22 | 2015-07-08 | 南京欧信医药技术有限公司 | 一种嘧啶类衍生物的合成方法 |
WO2015037018A1 (en) * | 2013-09-14 | 2015-03-19 | Ind-Swift Laboratories Limited | Process for the preparation of rosuvastatin via novel intermediates |
EP3115367B1 (en) | 2014-03-07 | 2017-11-01 | Asymchem Laboratories (Tianjin) Co., Ltd. | Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom |
CN103936680B (zh) * | 2014-04-18 | 2016-08-24 | 润泽制药(苏州)有限公司 | 瑞舒伐他汀钙已知杂质的制备方法 |
CN104788387A (zh) * | 2015-04-17 | 2015-07-22 | 浙江海森药业有限公司 | 高纯度瑞舒伐他汀钙的制备方法 |
KR20160126700A (ko) | 2015-04-24 | 2016-11-02 | 미래파인켐 주식회사 | 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법 |
CN105461636A (zh) * | 2015-12-30 | 2016-04-06 | 安徽美诺华药物化学有限公司 | 一种瑞舒伐他汀甲酯的合成方法 |
CN106478518A (zh) * | 2016-09-27 | 2017-03-08 | 南通常佑药业科技有限公司 | 一种庚烯酸环戊酯衍生物的制备方法 |
KR101953575B1 (ko) | 2016-10-24 | 2019-05-24 | 한양대학교 에리카산학협력단 | 스타틴계 고지혈증 치료제 합성을 위한 새로운 중간체 합성 및 이를 이용한 로수바스타틴 합성 공정 개발 |
CN108997324A (zh) * | 2018-08-21 | 2018-12-14 | 南京欧信医药技术有限公司 | 瑞舒伐他汀钙中间体的制备方法 |
CN109651259B (zh) * | 2018-12-29 | 2020-05-19 | 浙江永太科技股份有限公司 | 一种瑞舒伐他汀钙关键中间体的纯化方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3741509A1 (de) * | 1987-12-08 | 1989-06-22 | Hoechst Ag | Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
FR2741620B1 (fr) * | 1995-11-28 | 1997-12-26 | Oreal | Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline |
-
1999
- 1999-02-17 GB GBGB9903472.0A patent/GB9903472D0/en not_active Ceased
-
2000
- 2000-02-15 EE EEP200100430A patent/EE05150B1/xx unknown
- 2000-02-15 KR KR1020017010439A patent/KR100648160B1/ko active IP Right Grant
- 2000-02-15 JP JP2000599753A patent/JP2003518474A/ja not_active Withdrawn
- 2000-02-15 AR ARP000100642A patent/AR022600A1/es active IP Right Grant
- 2000-02-15 AT AT00903810T patent/ATE415398T1/de active
- 2000-02-15 CN CNB008037043A patent/CN1145625C/zh not_active Expired - Lifetime
- 2000-02-15 WO PCT/GB2000/000481 patent/WO2000049014A1/en active IP Right Grant
- 2000-02-15 EP EP00903810A patent/EP1155015B1/en not_active Expired - Lifetime
- 2000-02-15 ES ES00903810T patent/ES2316349T3/es not_active Expired - Lifetime
- 2000-02-15 DE DE60040905T patent/DE60040905D1/de not_active Expired - Lifetime
- 2000-02-15 TR TR2001/02360T patent/TR200102360T2/xx unknown
- 2000-02-15 TR TR2004/01874T patent/TR200401874T2/xx unknown
- 2000-02-15 MX MXPA01008235A patent/MXPA01008235A/es active IP Right Grant
- 2000-02-15 PL PL350185A patent/PL218518B1/pl unknown
- 2000-02-15 RU RU2001125421/04A patent/RU2243969C2/ru active
- 2000-02-15 BR BRPI0008301A patent/BRPI0008301B8/pt not_active IP Right Cessation
- 2000-02-15 AU AU25573/00A patent/AU760145B2/en not_active Expired
- 2000-02-15 DK DK00903810T patent/DK1155015T3/da active
- 2000-02-15 NZ NZ513261A patent/NZ513261A/en not_active IP Right Cessation
- 2000-02-15 EE EEP200900043A patent/EE05531B1/xx unknown
- 2000-02-15 US US09/913,539 patent/US6844437B1/en not_active Expired - Lifetime
- 2000-02-15 HU HU0200301A patent/HU229835B1/hu unknown
- 2000-02-15 IL IL14479300A patent/IL144793A0/xx not_active IP Right Cessation
- 2000-02-15 CZ CZ20012930A patent/CZ299844B6/cs not_active IP Right Cessation
- 2000-02-15 CA CA002362594A patent/CA2362594C/en not_active Expired - Fee Related
- 2000-02-15 PT PT00903810T patent/PT1155015E/pt unknown
- 2000-02-15 SI SI200031016T patent/SI1155015T1/sl unknown
- 2000-02-15 SK SK1183-2001A patent/SK286988B6/sk not_active IP Right Cessation
- 2000-03-10 TW TW089104365A patent/TWI285202B/zh not_active IP Right Cessation
-
2001
- 2001-07-31 IS IS6029A patent/IS2709B3/is unknown
- 2001-08-02 ZA ZA200106370A patent/ZA200106370B/xx unknown
- 2001-08-16 NO NO20013994A patent/NO320739B1/no not_active IP Right Cessation
-
2002
- 2002-04-22 HK HK02103022.4A patent/HK1041265B/zh not_active IP Right Cessation
-
2003
- 2003-07-02 US US10/610,700 patent/US6784171B2/en not_active Expired - Lifetime
- 2003-11-12 CL CL200302336A patent/CL2003002336A1/es unknown
-
2004
- 2004-08-05 IL IL163375A patent/IL163375A/en not_active IP Right Cessation
-
2007
- 2007-05-08 JP JP2007123108A patent/JP4130844B2/ja not_active Expired - Lifetime
-
2008
- 2008-03-17 JP JP2008067100A patent/JP2008255114A/ja active Pending
-
2009
- 2009-01-29 CY CY20091100107T patent/CY1108733T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL144793A0 (en) | Process for the production of tert-butyl (e)-(6-[2[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl] (4r,6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate | |
GB0003305D0 (en) | Pyrimidine derivatives | |
HK1092462A1 (en) | Process for the manufacture of the calcium salt of rosuvastatin (e)-7-[4- (4-fluorophenyl) -6-isopropyl-2-[methyl(methylsulfonyl) amino]pyrimidin -5- yl] (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof | |
HK1118209A1 (en) | Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6- enoic acid | |
CA2429263A1 (en) | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia | |
IL158588A0 (en) | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) - methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinase inhibitors | |
WO2003002580A8 (en) | 6-`2-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity | |
AU2992800A (en) | Process for the preparation of 6-(perfluoroalkyl)uracil compounds | |
CZ20012431A3 (cs) | Způsob výroby (4R,6R)tert-butyl[6-(2-aminoethyl)-2,2-dimethyl[1,3]dioxan-4-yl]acetatu a meziproduktů pro jeho výrobu | |
EP1065202A4 (en) | 6- (ALPHA-FLUOROALKYL) -4-PYRIMIDONES AND THEIR PRODUCTION PROCESS | |
AU6434900A (en) | Method for the production of 4,6-dichloropyrimidine with the aid of phosgene | |
AU3231500A (en) | Process for the preparation of 6-(perfluoroalkyl) uracil compounds from urea compounds | |
AU1657900A (en) | Process for the preparation of pyrimidinone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |